EQUIPT: Evaluating Quality of life In Period Treatment
K
Kerry Hege, MD
Primary Investigator
Administratively Closed
9 years - 21 years
Female
Phase
N/A
100 participants needed
2 Locations
Brief description of study
What is the purpose of this study?
The primary objective is to characterize the comparative effectiveness of hormonal therapy (combined oral contraceptives and progesterone methods), antifibrinolytic therapy, and intrauterine devices in the treatment of heavy menstrual bleeding (HMB) in adolescent females with an underlying bleeding disorder.
THIS STUDY IS ENROLLING BY INVITATION ONLY - Only eligible female patients that have been referred by a physician or self-referred to and seen by section of Pediatric Hematology/Oncology and Adolescent Medicine staff will be invited to participate in the clinical trial. Potential subjects will be contacted in the hospital or at a clinic visit in Pediatric Hematology/Oncology or Adolescent Medicine.
Detailed description of study
What will happen during the study?
- For this study you will be asked to complete surveys at three different times, more often if you begin new medications.
- These surveys will ask you questions about your health, your therapy, and your menstrual cycle.
- We will also look at your medical records so we can better understand your health and medical history. Surveys may be completed via email.
- This study will take place at Riley Hospital for Children and will last for 15 months.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Menorrhagia, Von Willebrand disease, Hemophilia, Riley
-
Age: 9 years - 21 years
-
Gender: Female
Inclusion Criteria:
Natal female, with uterus present, and menstruating
Age 9-21 years
Self-reported heavy menstrual bleeding
Diagnosed bleeding disorder OR undergoing evaluation for a bleeding disorder
Exclusion Criteria:
Currently pregnant or has been pregnant in the past 3 months
Bleeding disorder previously ruled out
On current menstrual suppression >12 months (known bleeding disorder) or >60 days (bleeding disorder evaluation)
Current anticoagulation treatment
Updated on
11 Feb 2025.
Study ID: PHO-EMORY-EQUIPT, 12874
